| Literature DB >> 30062099 |
Robin L Gabriels1,2, Zhaoxing Pan1,2, Noémie A Guérin3, Briar Dechant1,2, Gary Mesibov4.
Abstract
This paper presents 6-month follow-up data of 44% (N = 64/116) of participants (ages 6-16 years) with a diagnosis of autism spectrum disorder, who participated in a previously-published randomized controlled trial of therapeutic horseback riding (THR) compared to a no-horse contact active control. The objective of this study was to examine whether significant improvements of irritability, hyperactivity, social, and communication behaviors observed in participants randomized to receive a 10-week manual-based THR intervention were sustained 6 months after the intervention conclusion. Participants' caregivers from both the THR (n = 36) and active control (n = 28) groups completed a measure of irritability and hyperactivity behaviors (primary outcome variables). Additionally, only the THR group participants completed the full battery of study outcomes assessments. Between group comparisons examining the extended interval from baseline (1-month pre-intervention assessment) to 6-months after the intervention revealed that the THR group maintained reductions in irritability behavior at a 0.1 level (effect size = 0.32, p = 0.07). (Effect size = 0.32, p = 0.07), which was 73% of efficacy preserved from the primary post-intervention endpoint (within 1-month post-intervention). Hyperactivity behaviors did not sustain this same trend. Comparisons from baseline and 6-months after the intervention revealed that the THR group sustained significant initial improvements made in social and communication behaviors, along with number of words and different words spoken during a standard language sample. This is the first known study to examine and demonstrate the longer-term effects of THR for individuals with ASD and warrants a more thorough evaluation of whether the effects of THR are maintained for at least 6-months after the intervention compared to a control. CLINICAL TRIAL REGISTRATION INFORMATION: Trial of Therapeutic Horseback Riding in Children and Adolescents with Autism Spectrum Disorder; http://clinicaltrials.gov; NCT02301195.Entities:
Keywords: animal-assisted interventions; autism spectrum; irritability; long-term outcomes; therapeutic horseback riding
Year: 2018 PMID: 30062099 PMCID: PMC6054954 DOI: 10.3389/fvets.2018.00156
Source DB: PubMed Journal: Front Vet Sci ISSN: 2297-1769
Demographics for participants with follow-up at 6 months' post-treatment and those without follow-up.
| No. of participants | 36 | 28 | 64 | 22 | 30 | |||
| Age, [Mean (SD)], years | 10.7 (2.9) | 9.4 (2.5) | 10.1 (2.8) | 10.3 (3.7) | 0.67 | 10.5 (2.8) | 0.14 | |
| Gender, males/females (counts) | 29/7 | 25/3 | 54/10 | 0.34 | 20/2 | 0.46 | 27/3 | 1.0 |
| IQ [Mean (SD)] | 88.4 (25.1) | 89.2 (19.8) | 88.8(22.8) | 0.89 | 83.8 (26.4) | 0.51 | 83.1 (25.2) | 0.31 |
| Repetitive behavior scale total score [Mean (SD)] | 38.1 (22.4) | 37.2 (19.8) | 37.7 (21.0) | 0.86 | 37.7 (18.7) | 0.94 | 38.9 (20.1) | 0.74 |
| Community psychiatric diagnoses, Y/N(Counts) | 18/18 | 11/17 | 29/35 | 0.45 | 10/12 | 0.79 | 17/13 | 0.20 |
| Mood disorder, Y/N(Counts) | 6/30 | 5/23 | 11/53 | 1.0 | 2/20 | 0.70 | 7/23 | 0.75 |
| Anxiety disorder, Y/N(Counts) | 10/26 | 2/26 | 12/52 | 6/16 | 1.0 | 7/23 | 0.15 | |
| ADHD, Y/N(Counts) | 10/26 | 8/20 | 18/46 | 1.0 | 7/15 | 0.78 | 8/22 | 1.0 |
| Learning disability, Y/N(Counts) | 3/33 | 8/20 | 11/53 | 0.25 | 0/22 | 0.28 | 1/29 | 1.0 |
| Current seizure disorder, Y/N(Counts) | 1/35 | 0/28 | 1/63 | 1.0 | 0/22 | 1.0 | 2/28 | 0.49 |
| Psychotropic medicine, Y/N(Counts) | 17/19 | 11/17 | 18/36 | 0.53 | 10/12 | 1.0 | 18/12 | 0.19 |
| Distance traveled to riding center [mean (SD)] | 28.3 (6.4) | 22/0 (5/4) | 25.5 (19.3) | 0.20 | 34.92(19.5) | 0.20 | 31.6 (16.6) | |
| Latino/Hispanic, Y/N(Counts) | 5/31 | 5/23 | 10/54 | 0.66 | 5/17 | 0.48 | 6/23 | 1.0 |
| Race (counts) | 0.24 | 0.38 | 0.90 | |||||
| American Indian or Alaska native | 0 | 2 | 2 | 0 | 1 | |||
| Asian/ Hawaiian/Pacific Islander | 0 | 2 | 2 | 2 | 1 | |||
| Black or African American | 1 | 0 | 1 | 0 | 0 | |||
| White | 30 | 20 | 50 | 18 | 25 | |||
| Mixed Race | 4 | 1 | 5 | 1 | 1 | |||
| Other | 1 | 2 | 3 | 0 | 2 | |||
| Missing | 0 | 1 | 2 | 1 | 0 | |||
p-value for comparisons between THR and Barn group among participants with 6-month follow-up.
p-values for comparisons between participants with 6-month follow-up and those without respectively for THR and Barn participants.
p < 0.05;
p < 0.1 (Significant p-values are in bold).
Results of repeated measures analysis of variance (N = 36 for THR and N = 28 for Barn group)a.
| Irritability | Barn | 14.43 (8.69) | 11.96 (9.29) | 11.50 (7.87) | 2.46 (1.10) | 2.93 (1.10) | 0.46 (1.10) | 0.67 | ||||
| THR | 15.86 (9.52) | 9.00 (8.08) | 9.69 (6.87) | 6.86 (1.42) | < | 6.17 (1.42) | < | −0.69 (1.42) | 0.63 | |||
| Difference | −1.43 (2.13) | 2.96 (2.13) | 1.81 (2.13) | −4.40 (1.79) | 0.44 | −3.24 (1.79) | 0.32 | 0.07 | 1.16 (1.79) | 0.52 | ||
| Hyperactivity | Barn | 20.71 (20.75) | 17.07 (13.28) | 15.86 (14.81) | 3.64 (1.59) | 4.86 (1.59) | 1.21 (1.59) | 0.45 | ||||
| THR | 20.75 (20.71) | 13.28 (17.07) | 14.81 (15.86) | 7.47 (1.43) | < | 5.94 (1.43) | < | −1.53 (1.43) | 0.29 | |||
| Difference | −0.04 (2.48) | 3.79 (2.48) | 1.05 (2.48) | −3.83 (2.14) | 0.32 | 0.08 | −1.09 (2.14) | 0.09 | 0.61 | 2.74 (2.14) | 0.20 |
Sample means and standard deviation (SD) were reported for Baseline, end of 10-week treatment (EOT) and 6 month intervention follow-up. Mean and standard errors for change between time points and between-group difference (Baseline minus EOT, Baseline minus 6 months, & EOT minus 6 months). P-values for the overall test of time by group interaction were 0.0431 for irritability and 0.1868 for hyperactivity.
Cohen's D Effect size for efficacy at EoT or 6 months, estimated by 2 times t value divided by sqrt (DF).
p < 0.05;
p < 0.1.
Figure 1Profile of irritability (IRR) and hyperactivity (HYP) over three assessment periods. Note, the typical clinical threshold for the ABC-C irritability subscale is >14–16 in psychopharmacology clinical trials for the ASD population [e.g., (27, 28)].
Figure 2Mean scores at baseline, post-intervention and 6 months after THR.